Loading...
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
PURPOSE: Aurora A kinase (AAK) is upregulated in highly proliferative lymphomas, suggesting its potential as a therapeutic target. Alisertib is a novel oral AAK inhibitor without adverse safety signals in early-phase studies that demonstrated preliminary activity in T-cell lymphoma. This phase II st...
Na minha lista:
| Udgivet i: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Clinical Oncology
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4500834/ https://ncbi.nlm.nih.gov/pubmed/26077240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.6327 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|